Araújo A, et al. Avaliação económica do erlotinib, docetaxel, pemetrexedo e tratamento de suporte no tratamento de segunda ou terceira linhas de doentes com cancro do pulmão de não pequenas células Rev Port Pneumol 2008; 14(6):803-8271

doi:10.1016/S0873-2159(15)30155-0

Article information

Download PDF

Statistics

Full text is only aviable in PDF

Bibliografia/Bibliography

[1..]

A. Araujo, et al.

An economic analysis of erlotinib, docetaxel, pemetrexed and best supportive care as second or third line treatment of non-small cell lung cancer.

Rev Port Pneumol, 14 (2008), pp. 803-827

Medline

[2..]

P. Peterson, et al.

Is pemetrexed more effective in patients with non-squamous histology? A retrospective analysis of a phase III trial of pemetrexed vs. docetaxel in previously treated patients with advanced nonsmall cell lung cancer (NSCLC). Abstract P#6521, The European Cancer Conference 2007 (ECCO 14).

Eur J Cancer, 5 (2007), pp. 363

Article

[3.]

M. Drummond, M. Sculpher, G. Torrance, et al.

Methods for the economic evaluation of health care programmes, Third, pp. 48-51

[4.]

F. Song, et al.

Validity of indirect comparison for estimating efficacy of competing interventions: empirical evidence from published meta-analyses.

BMJ, 326 (2003), pp. 472

http://dx.doi.org/10.1136/bmj.326.7387.472 | Medline

[5.]

A.M. Glenny, D.G. Altman, F. Song, C. Sakarovitch, J.J. Deeks, R. D’Amico, et al.

Indirect comparisons of competing interventions.

Health Technol Assess, 9 (2005),

[6.]

A.E. da Silva, et al.

Orientações metodológicas para estudos de avaliação económica de medicamentos.

http://www.infarmed.pt/portal/page/portal/infarmed/medicamentos_uso_humano/avaliacao_economica_e_comparticipacao/medicamentos_uso_ambulatorio/avaliacao_de_comparticipacao/orien_metodologicas_eaem.pdf

[7.]

CHMP.

(2008)http://www.emea.europa.eu/humandocs/Humans/EPAR/alimta/alimta.htm

[8.]

CHMP.

(2008)http://www.emea.europa.eu/humandocs/Humans/EPAR/tarceva/tarceva.htm

[9.]

CHMP.

(2008)http://www.emea.europa.eu/humandocs/Humans/EPAR/taxotere/taxotere.htm

[10.]

N. Hanna, F.A. Shepherd, F.V. Fossela, et al.

Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy.

J Clin Oncol, 22 (2004), pp. 1589-1597

http://dx.doi.org/10.1200/JCO.2004.08.163 | Medline

[11.]

Erlotinib for the treatment of non-small cell lung cancer.

(2008)http://www.nice.org.uk/Guidance/TA162

[12.]

F.A. Shepherd, J. Pereira, T. Ciuleanu, et al.

Erlotinib in previously treated non-small cell lung cancer.

N Engl J Med, 353 (2005), pp. 123-132

http://dx.doi.org/10.1056/NEJMoa050753 | Medline

[13.]

F.A. Shepherd, et al.

Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with plati-num-based therapy.

Journal of Clinical Oncology, 18 (2000), pp. 2095-2103

http://dx.doi.org/10.1200/jco.2000.18.10.2095 | Medline

[14.]

M. Drummond, M. Sculpher, G. Torrance, et al.

Methods for the economic evaluation of health care programmes, Third, pp. 13

[15.]

J. Arellano, C. Leteneux, W. Kotowa, et al.

Letter to the Editor: A comparison of the estimated costs of erlotinib, docetaxel and pemetrexed for the second-line treatment of non-small cell lung cancer from the German healthcare perspective.

Journal of Medical Economics, 11 (2008), pp. 363-370

http://dx.doi.org/10.3111/13696990802113147 | Medline

Leituras adicionais/Further readings

[NICE Technology Appraisal TA124]

NICE Technology Appraisal TA124.

Pemetrexed for the treatment of non-small-cell lung cancer.

(August 2007)http://www.nice.org.uk/Guidance/TA124

[American Pharmaceutical Group]

American Pharmaceutical Group criticizes NICE approach vs. Alimta: UK parliamentary Select Committee on Health documents: http://www.publications.parliament.uk/pa/cm200607/cmselect/cmhealth/503/503we06.htm